Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CNBX Pharmaceuticals ( (CNBX) ) has provided an announcement.
On March 10th, 2026, CNBX Pharmaceuticals entered into a non-convertible promissory note with 3i L.P. for $45,000, bearing simple interest of 5% per annum and maturing on July 1st, 2026. The company indicated that the funds will be used for immediate working capital needs and expenditures, underscoring its near-term liquidity requirements and reliance on short-term financing to support ongoing operations.
This transaction reflects a modest but targeted capital infusion that may help CNBX Pharmaceuticals maintain operational continuity in the coming months. By opting for a non-convertible structure, the company avoids near-term equity dilution, while signaling to stakeholders that it is actively managing cash flow and short-term obligations through debt financing.
More about CNBX Pharmaceuticals
CNBX Pharmaceuticals operates in the pharmaceuticals industry, focusing on developing medical treatments and related healthcare solutions. The company’s activities require ongoing access to working capital to fund its operations, research, and general corporate expenditures in a capital-intensive market.
Technical Sentiment Signal: Sell
Current Market Cap: $130.6K
For detailed information about CNBX stock, go to TipRanks’ Stock Analysis page.